Policy Developments - Liaoning Province will implement direct payment of maternity allowances to employees starting November 1, 2025, enhancing convenience and satisfaction for the public [1] Drug and Device Approvals - Hengrui Medicine's subsidiary received clinical trial approval for injection of Rukang Qutuzumab, aimed at treating advanced non-small cell lung cancer [2] - Jibeier received approval for the market application of the chemical raw material drug, Gatifloxacin, which is expected to support its production needs [3] Financial Reports - Ping An Good Doctor reported a 13.6% increase in revenue to 3.725 billion, with a net profit of 216 million, up 45.7% year-on-year [4] - Te Yi Pharmaceutical achieved a 985% increase in net profit, reporting 65.22 million in the first three quarters, with significant growth in traditional Chinese medicine sales [5] - Lijun Pharmaceutical reported a revenue of 9.116 billion, a slight increase of 0.38%, with a net profit of 1.754 billion, up 4.86% [6] Capital Market - In Shanghai's Baoshan District, 17 key biopharmaceutical projects were signed, with total investments exceeding 2 billion, aimed at enhancing the local biopharmaceutical industry [7][8] Industry Developments - Baiyang Pharmaceutical signed a cooperation agreement with Peking University International Hospital to establish a radiosurgery treatment center, enhancing access to high-quality medical resources [10] - Qiang Brain Technology established a new company in Chengdu focusing on AI-related businesses, including medical devices and internet data services [11] Regulatory Actions - The Shanghai Stock Exchange issued a regulatory warning to Zhejiang Dongya Pharmaceutical for discrepancies in the use of raised funds, highlighting the responsibility of the company's former board secretary [12]

Core Viewpoint - Zhejiang Dongya Pharmaceutical Co., Ltd. is facing regulatory scrutiny due to discrepancies in the use of raised funds compared to what was disclosed in its IPO prospectus, leading to a warning for its former board secretary and ongoing financial challenges for the company [1][2][3]. Group 1: Regulatory Issues - Zhejiang Securities Regulatory Bureau found that Dongya Pharmaceutical's actual use of raised funds did not align with the disclosures made in its IPO prospectus, and the company failed to follow internal review procedures for these changes [2]. - The company has been ordered to rectify these issues, and the violations will be recorded in the securities market's integrity archives [2][3]. Group 2: Financial Performance - Dongya Pharmaceutical's revenue for 2022, 2023, 2024, and the first half of 2025 were reported at 1.18 billion, 1.36 billion, 1.20 billion, and 416 million respectively, with year-on-year growth rates of 65.62%, 15.00%, -11.66%, and -35.85% [4]. - The net profit attributable to shareholders for the same periods was 104 million, 121 million, -101 million, and -30.23 million, with year-on-year growth rates of 52.46%, 16.11%, -183.02%, and -193.09% [4]. - The company's debt-to-asset ratio has increased from 25.56% in 2022 to 47.70% in the first half of 2025, indicating rising financial leverage [4]. Group 3: Business Challenges - Dongya Pharmaceutical's core antibacterial drug business is under significant pressure due to the government's "antibiotic restriction orders," which have limited the market space for antibacterial drugs [5][6]. - The company has attempted to implement a "raw material drug formulation integration" strategy, but progress has been slow, with only one of over ten submitted formulations receiving approval [7]. - The existing product structure remains heavily reliant on antibacterial drugs, exposing the company to substantial market and policy risks [7].

Core Points - Zhejiang Dongya Pharmaceutical Co., Ltd. has been ordered to rectify its fundraising practices due to discrepancies between the actual use of funds and the disclosures made in its initial public offering prospectus [1][5][6] - The company reported a significant decline in revenue and net profit for the first half of 2025, with a revenue of 416 million yuan, down 35.85% year-on-year, and a net loss of approximately 30.23 million yuan [1] - Dongya Pharmaceutical's stock is currently trading below its initial offering price, indicating a state of underperformance since its listing [2] Fundraising and Financial Performance - The company raised a total of 884 million yuan during its IPO, with a net amount of 782 million yuan allocated for various projects, including the production of key intermediates and raw materials for antibiotics [2][4] - In 2024, Dongya Pharmaceutical's revenue was 1.198 billion yuan, a decrease of 11.66% year-on-year, with a net loss of 101 million yuan, reflecting a 183.02% decline compared to the previous year [1] - The company has conducted two fundraising rounds since its listing, totaling 1.574 billion yuan [4]

对此，浙江证监局决定对公司采取责令改正的监督管理措施，并记入证券期货市场诚信档案。 近日，东亚药业（605177）发布公告称，公司于近日收到浙江证监局《关于对浙江东亚药业股份有限公 司采取责令改正措施的决定》。 浙江证监局在现场检查中发现，东亚药业部分募集资金用途与首次公开发行股票招股说明书中披露的用 途不一致，公司未及时履行审议程序，关于募集资金存放与实际使用情况的相关信息披露不准确。 ...

Core Points - East Asia Pharmaceutical (605177.SH) received a corrective measure order from the Zhejiang Regulatory Bureau of the China Securities Regulatory Commission due to discrepancies in the use of raised funds compared to the disclosures in the initial public offering prospectus [1] - The Zhejiang Regulatory Bureau found that the company did not timely perform the necessary review procedures and that the information disclosed regarding the storage and actual use of raised funds was inaccurate [1] - As a result, the Zhejiang Regulatory Bureau decided to implement corrective supervisory measures and record this incident in the securities and futures market integrity file [1]

Group 1 - Cinda Biologics has reached a global strategic cooperation with Takeda Pharmaceutical, aiming to accelerate the development of new generation IO and ADC therapies, with a total deal value potentially reaching $11.4 billion [1] - The collaboration includes two late-stage therapies, IBI363 and IBI343, and an early-stage project, IBI3001, with an upfront payment of $1.2 billion, including $100 million in strategic equity investment [1] - Cinda Biologics is expected to maximize the long-term commercialization prospects of IBI363 and IBI343 globally, leveraging Takeda's strong presence in the gastrointestinal oncology field [1] Group 2 - Shouyao Holdings announced that its self-developed RET inhibitor, SY-5007, has received acceptance for a new drug application for treating RET fusion-positive locally advanced or metastatic non-small cell lung cancer [2] - SY-5007 is a highly selective small molecule RET tyrosine kinase inhibitor and is among the fastest progressing fully domestic RET inhibitors in clinical research [2] - If approved, SY-5007 will fill the gap in domestic RET inhibitors, as currently only two RET inhibitors, pralsetinib and selpercatinib, have been approved globally [2] Group 3 - Dongya Pharmaceutical has been ordered to rectify discrepancies between the use of raised funds and disclosures in its IPO prospectus, as identified by the Zhejiang Securities Regulatory Bureau [3] - The company failed to timely follow the review procedures regarding the actual use of raised funds, leading to inaccurate disclosures [3] - This incident highlights the need for listed companies to enhance transparency and compliance in information disclosure [3] Group 4 - ST Nuotai reported a revenue of approximately 1.527 billion yuan for the first three quarters of 2025, representing a year-on-year increase of 21.95%, with a net profit of about 445 million yuan, up 26.92% [4] - In the third quarter, the company achieved revenue of approximately 479 million yuan, a year-on-year growth of 13.82%, and a net profit of about 134 million yuan, increasing by 9.27% [4] - The growth in ST Nuotai's performance is attributed to the rapid increase in demand for peptide raw materials, with oral peptide products expected to become a new growth point for the company [4]

Core Points - East Asia Pharmaceutical (605177) received a corrective measure order from the Zhejiang Securities Regulatory Bureau due to discrepancies in the use of raised funds compared to the disclosures in the initial public offering prospectus [1] - The Zhejiang Securities Regulatory Bureau found that the company did not timely fulfill the review procedures and that the information disclosure regarding the storage and actual use of raised funds was inaccurate [1] - As a result, the Zhejiang Securities Regulatory Bureau decided to implement corrective supervision measures and record this in the securities and futures market integrity file [1]

浙江东亚药业股份有限公司 关于公司收到浙江证监局行政监管措施决定书的公告 | 证券代码：605177 | 证券简称：东亚药业 公告编号：2025-048 | | --- | --- | | 债券代码：111015 | 债券简称：东亚转债 | 上述行为违反了《上市公司信息披露管理办法》（证监会令第 182 号）第三 条第一款，《上市公司监管指引第 2 号--上市公司募集资金管理和使用的监管要 求》（证监会公告【2022】15 号）第六条、第十二条第一款的有关规定。 根据《上市公司信息披露管理办法》（证监会令第 182 号）第五十二条的规 定，我局决定对你公司采取责令改正的监督管理措施，并记入证券期货市场诚信 档案。你公司应积极采取措施，消除违规行为影响，加强证券法律法规学习，切 实规范募集资金的管理与使用，杜绝此类行为再次发生，并于收到本决定书之日 起 10 个工作日内向我局提交书面整改报告。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 如对本监督管理措施不服，可在收到本决定书之日起 60 日内向中国证券监 督管理委员会提出 ...

上交所发布对浙江东亚药业股份有限公司及时任董事会秘书贾飞龙予以监管警示的决定。内容显示，浙 江东亚药业股份有限公司部分募集资金用途与首次公开发行股票招股说明书中披露的用途不一致，公司 未及时履行审议程序，且关于募集资金存放与实际使用情况的相关信息披露不准确。责任人方面，公司 时任董事会秘书贾飞龙作为公司信息披露事务的具体负责人，未能勤勉尽责，对上述违规负有责任。鉴 于上述违规事实和情节，上交所对浙江东亚药业股份有限公司及时任董事会秘书贾飞龙予以监管警示。 ...

| | | 浙江东亚药业股份有限公司 关于可转债转股结果暨股份变动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 累计转股情况：截至 2025 年 9 月 30 日，累计已有人民币 23,779,000 元 "东亚转债"转为公司 A 股普通股，累计转股股数为 1,154,021 股，占"东亚转 债"转股前公司已发行普通股股份总额的 1.0159%。 未转股可转债情况：截至 2025 年 9 月 30 日，尚未转股的"东亚转债" 金额为人民币 666,221,000 元，占"东亚转债"发行总量的比例为 96.5538%。 本季度转股情况：2025 年 7 月 1 日至 2025 年 9 月 30 日，共有 5,000 元 "东亚转债"转为公司 A 股普通股，转股股数为 245 股。 一、"东亚转债"发行上市概况 经上海证券交易所（以下简称"上交所"）自律监管决定书〔2023〕166 号 文同意，公司发行的 69,000 万元可转换公司债券于 2023 年 8 月 2 日起在上交所 挂牌交易，债券简称"东亚转 ...